IEAIX Performance — Lazard International Equity Advantage Portfolio, Institutional Shares
Data updated: 2025-05-28
IEAIX returned +12.84% over one year to Mar 2025. Annualised returns are +10.42% over 3 years and +14.16% over 5 years. The fund beat its International Mid-Cap Blend category average: $100 invested three years ago grew to $135, against $116 for the category, and to $113 over one year, against $105. Volatility over the past three years was 17.13% a year. In the 12 months to Mar 2025 the fund took in a net $13.9M, and assets reached $36.70M.
IEAIX Growth of $100
What $100 invested in Lazard International Equity Advantage Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the International Mid-Cap Blend category average over the same months.
| Period | IEAIX | Category average |
|---|---|---|
| 1 year (Apr 2024 – Mar 2025) | $113 | $105 |
| 3 years (Apr 2022 – Mar 2025) | $135 | $116 |
| 5 years (Apr 2020 – Mar 2025) | $194 | $169 |
| Since data start (Jul 2019 – Mar 2025) | $159 | $140 |
IEAIX Trailing Returns
Total returns to Mar 2025, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | +12.84% |
| 3 years (annualised) | +10.42% |
| 5 years (annualised) | +14.16% |
IEAIX Annual Returns
Calendar-year total returns of Lazard International Equity Advantage Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2025 (Jan–Mar) | +8.56% |
| 2024 | +11.69% |
| 2023 | +19.81% |
| 2022 | −13.45% |
| 2021 | +13.94% |
| 2020 | +5.41% |
| 2019 (Jul–Dec) | +5.28% |
IEAIX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +4.5% | +3.1% | +0.8% | — | — | — | — | — | — | — | — | — |
| 2024 | −0.4% | +4.3% | +3.4% | −1.9% | +5.5% | −0.4% | +2.4% | +2.0% | +1.7% | −3.4% | +0.2% | −2.1% |
| 2023 | +8.5% | −2.1% | +2.3% | +2.0% | −4.0% | +5.2% | +3.6% | −3.9% | −2.4% | −2.9% | +8.5% | +4.5% |
| 2022 | −2.5% | −3.9% | −0.4% | −6.7% | +3.3% | −9.1% | +4.8% | −5.8% | −9.5% | +6.2% | +13.2% | −1.5% |
| 2021 | −1.1% | +3.1% | +3.5% | +3.1% | +4.1% | −1.3% | +1.4% | +1.5% | −4.5% | +3.0% | −4.5% | +5.3% |
| 2020 | −2.0% | −7.9% | −13.8% | +5.8% | +4.1% | +2.6% | +1.6% | +4.4% | −2.0% | −3.6% | +13.3% | +5.6% |
| 2019 | — | — | — | — | — | — | −2.9% | −2.6% | +2.8% | +3.3% | +1.1% | +3.7% |
IEAIX Risk
Risk measures from monthly returns over Apr 2022 – Mar 2025.
- 3-year volatility (annualised): 17.13%
- 3-year Sharpe ratio: 0.35 (vs 4.5% risk-free rate)
- Best month: +13.23% (Nov 2022)
- Worst month: −9.48% (Sep 2022)
IEAIX Fund Flows
Monthly money in and out of Lazard International Equity Advantage Portfolio, from SEC Form N-PORT.
- 12-month net flow: $13.9M
- 12-month gross sales (incl. reinvestments): $36.1M
- Sales ÷ redemptions: 1.63×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Mar 2025 | $21.0M | $19.5M | $1.5M |
| Feb 2025 | $446K | $303K | $143K |
| Jan 2025 | $5.4M | $279K | $5.2M |
| Dec 2024 | $1.9M | $188K | $1.7M |
| Nov 2024 | $5.2M | $565K | $4.7M |
| Oct 2024 | $551K | $77K | $474K |
| Sep 2024 | $149K | $188K | −$39K |
| Aug 2024 | $313K | $162K | $151K |
| Jul 2024 | $590K | $119K | $471K |
| Jun 2024 | $135K | $54K | $81K |
| May 2024 | $168K | $547K | −$379K |
| Apr 2024 | $258K | $277K | −$20K |
IEAIX Assets Under Management
Net assets of Lazard International Equity Advantage Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2025-03-31 | $36.70M |
| 2024-12-31 | $27.26M |
| 2024-09-30 | $23.06M |
| 2024-06-30 | $21.17M |
| 2024-03-31 | $20.85M |
| 2023-12-31 | $19.39M |
| 2023-09-30 | $2.92M |
| 2023-06-30 | $3.00M |
| 2023-03-31 | $2.89M |
| 2022-12-31 | $2.56M |
| 2022-09-30 | $2.16M |
| 2022-06-30 | $2.42M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.